VERV vs. APGE, AMPH, IOVA, TARS, IBRX, IRON, BLTE, WVE, ARQT, and GLPG
Should you be buying Verve Therapeutics stock or one of its competitors? The main competitors of Verve Therapeutics include Apogee Therapeutics (APGE), Amphastar Pharmaceuticals (AMPH), Iovance Biotherapeutics (IOVA), Tarsus Pharmaceuticals (TARS), ImmunityBio (IBRX), Disc Medicine (IRON), Belite Bio (BLTE), Wave Life Sciences (WVE), Arcutis Biotherapeutics (ARQT), and Galapagos (GLPG). These companies are all part of the "pharmaceutical products" industry.
Verve Therapeutics vs.
Verve Therapeutics (NASDAQ:VERV) and Apogee Therapeutics (NASDAQ:APGE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings, risk and community ranking.
Verve Therapeutics has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Comparatively, Apogee Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500.
In the previous week, Verve Therapeutics had 2 more articles in the media than Apogee Therapeutics. MarketBeat recorded 3 mentions for Verve Therapeutics and 1 mentions for Apogee Therapeutics. Verve Therapeutics' average media sentiment score of 0.38 beat Apogee Therapeutics' score of 0.15 indicating that Verve Therapeutics is being referred to more favorably in the media.
Verve Therapeutics and Apogee Therapeutics both received 24 outperform votes by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 53.33% of users gave Verve Therapeutics an outperform vote.
Apogee Therapeutics has lower revenue, but higher earnings than Verve Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.
Verve Therapeutics presently has a consensus target price of $25.75, indicating a potential upside of 319.38%. Apogee Therapeutics has a consensus target price of $89.71, indicating a potential upside of 142.08%. Given Verve Therapeutics' higher probable upside, equities analysts plainly believe Verve Therapeutics is more favorable than Apogee Therapeutics.
97.1% of Verve Therapeutics shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 19.3% of Verve Therapeutics shares are held by insiders. Comparatively, 36.1% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Apogee Therapeutics has a net margin of 0.00% compared to Verve Therapeutics' net margin of -807.65%. Apogee Therapeutics' return on equity of -21.81% beat Verve Therapeutics' return on equity.
Summary
Apogee Therapeutics beats Verve Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Verve Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VERV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verve Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VERV) was last updated on 1/21/2025 by MarketBeat.com Staff
Free VERV Stock Alerts